1. Medtronic’s goal is to generate $40 billion in free cash flow over the next five years, with half returned to shareholders as dividends and buybacks.
2. The company will allocate $10 billion of the $40 billion in free-cash-flow to debt reduction and bolt-on mergers and acquisitions. The remaining $10 is slated for flexible options including “bolstering the company’s cash position.”
3. Medtronic intends to achieve mid-single digit constant currency revenue growth in the next five years, as well as double-digit constant currency EPS.
4. Every Medtronic division plans to drive innovation and new product development. While the cardiac and vascular market is expected to grow at a 4 percent CAGR, the company wants to grow at a 9 percent CAGR.
5. Medtronic is benefiting from its Covidien merger and a marginally lower tax rate from relocating headquarters from the United States to Ireland; which has resulted in a 200 to 300 bps.
6. Medtronic will likely have access to 75 percent of the ongoing free-cash flow generation by 2021.
“Medtronic has ambitious growth plans over the next five years. Personally I am skeptical all the targets can be hit,” concluded the article’s author.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
